$$ Grant Life Sciences! Volumen lügt nicht! $$

;-)  

Volume: 33,082,177
Percent Change: +130.00
Last Sale: 0.0345 fast auf tageshoch einfach genial, cali hat wohl wieder den richtigen riecher gehabt, gruß nach Kuba;-) und morgen geht es weiter;-)  

 

die hat gestern 2200% gemacht???? Hallo,ist das richtig?
 

 

 

bei den Ami´s benannt:
otcstockexchange.com: GLIF OTCStockExchange.com Stock Alert
Grant Life Sciences, Inc. ( OTCBB: GLIF - http://finance.yahoo.com/q?s=GLIF.OB ) Grant Life Sciences, Inc. engages in the research, development, marketing, and sale of diagnostic kits for detecting low-grade cervical disease in the United States. The company's tests detect the presence of antibodies that are produced when cervical cancer or certain precancerous conditions are present in the body by analyzing a small amount of the patient's blood. It also holds worldwide rights to diagnostic devices for HIV-1, HIV-2, and dengue fever testing; and a proprietary diagnostic reagent, an ingredient used by manufacturers of rapid tests

OTCPicks.com: Daily Market Movers Digest Midday Stock Alerts, Monday, July 10th, GLIF

GRANT LIFE SCIENCES, INC. (OTCBB: GLIF) "Up 44% in morning trading"

Detailed Quote: http://www.otcpicks.com/quotes/GLIF.php

Grant Life Sciences Inc. (OTCBB: GLIF) develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious, or economic reasons. Further information is available at: www.grantlifesciences.com.

GLIF News:

July 7 - Grant Life Sciences Chairman Featured in Exclusive Interview With WallSt.net

On July 5, Stan Yakatan, Chairman of Grant Life Sciences, Inc. (OTC Bulletin Board: GLIF) updated the investment community in an exclusive interview with http://www.wallst.net. Topics covered in the interview include an overview of the Company and the markets it serves, recent press releases, current capitalization, upcoming strategic and financial milestones.

To hear the interview in its entirety, visit http://www.wallst.net , and click on "Interviews." Interviews require free registration, and can be accessed either by locating the respective company's ticker symbol under the appropriate exchange on the left-hand column of the "Interviews" section of the site, or by entering the respective company's ticker symbol in the Search Archive window.

und so sieht es aktuell in Berlin aus: Diff. in %:    +84,21%
also allen investierten noch viel Spaß und ein glückliches Händchen, aber vergeßt nicht "Gier frißt Hirn" und nehmt mal Gewinne mit bevor so ein Wert auch wieder mal die andere Richtung testet. Ich bin mit 103% von gestern auf heute raus, was nicht bedeutet dass die Party nicht weitergeht, aber Börse und insbesondere diese Werte laufen nicht in keiner Einbahnstraße;-)
Gruß Hausi
 

es ist so ruhig. wenn ja, was haltet ihr bis jetzt von GLIF?  

wurde nach 21Uhr bekannt

http://www.telecentro.pt/forum/ler_questao.asp?qt=219&varid=2

Assunto: Banco Espirito Santo will launch a takeover to Grant Life Sciences, Inc.

Enviada por: Nome: José Escarigo IP:  -->Data:   11-07-2006 19:49:34   e-mail:   Escarigo70@yahoo.com.br

Respostas:

Nenhuma

Questão: Lisbon - A source from Banco Espirito Santo (BES) said today that Banco Espirito Santo will launch a takeover to Grant Life Sciences, Inc. Banco Espirito Santo (BES), will notifie next friday the Portuguese National Securities Market Commission (CNMV) that it was willing to waive the condition of a 75% minimum acceptance level to which its public offer for the acquisition of Grant Life Sciences, Inc shares was subject, taking into consideration that the response received will be sufficient to develop the business project pursued through the takeover bid. Banco Espirito Santo (BES) will launch a takeover bid for Grant Life Sciences, Inc with the payment of $0.10 USD for each of the that responded to the tender offer, this initial offer could reach the limit of price of $0.12 USD for each share of the company. About Banco Espirito Santo : As one of the strongest and most traditional players in the Portuguese market, Banco Espírito Santo, founded in 1884, is Portugal's leading franchise when it comes to private banks. Its reputation has however crossed borders, making the Espírito Santo name internationally recognized and respected. Being in the forefront of International Business is definitely one of the achievements we want to keep. Our widespread presence across the globe, in over 50 cities in 17 countries, makes us the most international of Portuguese Banks and, most importantly, allows our customers - individuals, corporate, institutional, etc - to fully rely on our capability to serve their banking requirements in different geographies. Find out more about our International Presence and how it can also be of benefit to your Institution. Notwithstanding the fact that a large number of our international units are deeply related to the provision of services to Portuguese emigrant communities abroad, BES Group activities are as varied as its global spread. A list of the most relevant international activities helps summarizing the broad scope of BES global presence: Services to emigrant communities (account opening, savings accounts, remittances processing, etc) Foreign Trade Retail Banking Corporate Banking Private Banking Investment Banking Project Finance Wholesale Banking Treasury A team of committed relationship managers will provide you with all the assistance needed in devising the most adequate solutions whatever your Bank's specific needs are. Visit the Financial Institutions Group page to know more about its range of activities. http://www.otcpicks.com/quotes/GLIF.php

 

hast Du welche, habe mich heute auch wieder günstiger eingekauft nach dem ich ja gestern raus bin, Deine Meldung ist ja ein Kracher, da sollten wir ja in kürze wenigstens 0,5 sehen, was meinst Du?
Gruß Hausi  

wieder gigantisch, Richtung ist momentan +10 /- 15%, konnte da drüben auch noch keine Meldung bezüglich des Übernahmeangebotes finden, 3 Stockalert haben aber schon auf glif aufmerksam gemacht, mal sehen wie es weiter geht;-)  

... was bringt mir das, wenn der kurs nicht anspringt? ich bin auch gestern wieder rein, nachdem ich vorgestern verkauft habe. aber trotzdem. das ist so ähnlich wie bei amazon biotech: super news, mini-umsatz und der kurs springt auch nicht an.

aber ok, mal abwarten! ich bin ja nicht ungeduldig...  

2Mio. in einer Stunde, da gibt es gerade in diesem Segment welche die gerade mal bei 10K liegen;-) Also wenn die Meldung die RP reingestellt hat funzt dann kann es nur eine Richtung geben. Aber bis jetzt habe ich da drüben nichts lesen können von Übernahme, wenn das ein Alert bringt knallt es;-)  

nicht auf glif  

von übernahme habe ich auch nichts gefunden, ich weiß nicht, ob du diese news kennst (hier geht wieder um "hot stocks", news sind von heute):


Stock Market Alerts LLC: Hot Stock Lists for Wednesday! July 12, 2006
7/12/2006      

Miami, FLA., Jul 12, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Stock Market Alert's performance stock list includes: ER Urgent Care Centers (OTC: ERUG), Samaritan Pharmaceuticals Inc. (AMEX: LIV), Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX), Cambridge Heart, Inc. (OTCBB: CAMH), Grant Life Sciences Inc. (OTCBB: GLIF).

ER Urgent Care Centers (OTC: ERUG) should be of interest to speculative investors this morning. Yesterday the company issued a press release announcing that it has received a highly favorable report from an independent market analyst. ERUG is happy to report that the independent analysis speaks very highly as to the direction the company is going. Also in the analysis is that the methods being used by the company are on target in a booming industry.

This should be a stock for speculative investors to watch. The press release states ER Urgent (Care Centers) continues to grow in South Florida as well as nationwide. ER Urgent Care currently operates five locations in South Florida and another in Kansas City. Over the next two years, a plan of consistent growth in major markets is on tap for ER Urgent Care Centers. As community service programs are implemented in each of these communities, a steady expansion plan is in place.

ERUC Management Company Inc. operates ER Urgent Care Centers in the South Florida area. The "true, bona-fide," "Urgent Care Center" is a one-stop-shop where patients can receive premier health care, after-hours, at a fraction of the cost of emergency room visits. With the "Urgent Care Center" model, emergency rooms will no longer lose money on ER patients with minor injuries and illnesses, and the HMOs will no longer have to pay exorbitant claims for non-admitted patients. ER Urgent Care Centers create a win-win situation for everyone, filling the financial and service gap between primary care physicians (PCPs) and hospital emergency rooms.

Other Stocks of interest yesterday were:

Samaritan Pharmaceuticals Inc. (AMEX: LIV) up 30.7% on 2.6 million shares traded.

Samaritan is a small-cap Biotech, driven to discover, develop and commercialize innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease patients. Samaritan Pharmaceuticals Inc. recently announced, its Alzheimer's drug SP-233 (Caprospinol), not only stops amyloid plaque formation in the brain of an animal model for Alzheimer's disease but also shows that treatment with Caprospinol, results in the complete disappearance of amyloid plaques in the brain.

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) up 13.1% on 995,000 shares traded.

Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases. Idenix Pharmaceuticals, Inc. recently announced that Jean-Pierre Sommadossi, Ph.D., Idenix's chairman and chief executive officer, will present a corporate overview at the upcoming Pacific Growth Equities Life Sciences Growth Conference on Monday, June 12, 2006 at 9:00 a.m. PT at the InterContinental Mark Hopkins Hotel in San Francisco, at the Goldman Sachs 27th Annual Global Healthcare Conference on Tuesday, June 13, 2006 at 8:40 a.m. PT at the Ritz Carlton Laguna Niguel, and at the Needham and Co. Fifth Annual Biotechnology and Medical Technology Conference on Thursday, June 15, 2006 at 9:30 am ET at the New York Palace Hotel.

Cambridge Heart, Inc. (OTCBB: CAMH) up 8% on 986,000 shares traded.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Cambridge Heart, Inc. recently announced that it has hired Mr. Mark Florence as its Vice President, Sales and Marketing. Mr. Florence has extensive experience over the last 20 years in the cardiac medical device and diagnostic industry. He has held positions of increasing responsibility in marketing, sales and general management with industry leaders such as Abbott Laboratories, Bayer and the Moore Medical Subsidiary of McKesson.

Grant Life Sciences Inc. (OTCBB: GLIF) down 7.2% on 34.7 million shares traded.

Grant Life Sciences, Inc. is a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.

Grant Life Sciences Inc. recently announced it has extended through Sept. 2006 its Memo of Understanding (MOU) with Israel-based Diagnostic Technology Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593).

Under the MOU, Grant will receive an upfront payment of $250,000 upon successful completion of DTL's due diligence and the subsequent signing of a Licensing Agreement. Under the Licensing Agreement, DTL would assume all costs and efforts associated with commercialization of products, including clinical trials, developed by DTL from Grant's cervical cancer-diagnostic technology platform. Upon commercialization, DTL would pay Grant an ongoing royalty on sales of the products developed, according to the MOU.

Wall Street Enews is a Sponsor of Quality Stocks. Quality Stocks tracks the stock picks of 150 Investment Newsletters every day and reports on their performance. For Their Free Service, Visit www.qualitystocks.net.

The advertisement is provided by Wall Street Enews, a division of Stock Market Alerts LLC, an electronic broadcaster and publisher of this release, and hereafter referred to as "the company". The company received compensation for services performed, past and present, for ER Urgent Care Centers (OTC: ERUG). The compensation is five thousand dollars from ER Urgent Care Centers. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The information contained in this press release is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. Stock Market Alerts LLC is an advertising company and therefore, this release should be viewed for informational purposes only.

The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the advertising information contained in this release as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the public company that this release is providing service for should be reviewed as speculative and a high-risk and may result in the loss of some or all of any investment.

This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.

CONTACT: e-mail: info@wallstreetenews.com


 

ja habe ich schon gelesen, trotzdem danke, finde aber auch diese Nachricht recht Interessant, oder taugt mein english nix?
Gruß Hausi  

 

Volume: 5,782,875 also 600K in der letzten Stunde gehandelt und die gehen abwärts, denke da wird gedrückt zum günstig eindecken, sobald die Umsätze steigen und diese Übernahme-Story platziert wird wissen wir mehr;-)  

den Eigentümer gewechselt, denke nach der Mittagspause geht der Punk ab, hoffentlich nur in die richtige Richtung. Mach mich jetzt vom Acker und schaue später wieder rein wenn die ami´s auch durch sind.
Gruß Hausi  

Lissabon - Zur Quelle von Banco Espirito Santo (BES) sagte heute, dass Banco Espirito Santo der Übernahme zu Grant Life Sciences, Inc Banco Espirito Santo (BES) starten wird, notifie nächsten Freitag die portugiesische Staatssicherheitsmarktkommission (CNMV), dessen es bereit war, auf die Bedingung zu minimalem Annahmeniveau von 75 % zu verzichten, dem sein öffentliches Angebot für den Erwerb von Anteilen von Grant Life Sciences, Inc unterworfen war, in Betracht ziehend, dass die erhaltene Antwort genügend sein wird, um das durch das Übernahmeangebot verfolgte Geschäftsprojekt zu entwickeln. Banco Espirito Santo (BES) wird zum Übernahmeangebot für Grant Life Sciences, Inc mit der Zahlung des US-Dollars von 0.10 $ für jeden losfahren, dass Antwort auf, um Angebot zu neigen, dieses anfängliche Angebot die Grenze des Preises des US-Dollars von 0.12 $ für jeden Anteil der Gesellschaft erreichen konnte. Über Banco Espirito Santo: Experte einer der stärksten und traditionellsten Spieler auf dem portugiesischen Markt, Banco Espíritos Santo, gegründet 1884, ist Portugals führender franchize, wenn es Sie essen, um Sie Banken zu berauben. Sein Ruf ist jedoch durchquerte Grenzen, die Espírito Süßkartoffel von Santo international anerkannt und respektiert machend. In der vordersten Reihe des Internationalen Geschäfts zu sein, ist bestimmt eines der Ergebnisse, die wir behalten wollen. Unsere weit verbreitete Anwesenheit über den Erdball, in mehr als 50 Städten in 17 Ländern, macht uns die internationalsten von portugiesischen Banken und erlaubt am wichtigsten unseren Kunden - Personen, korporativ, Institutions- usw. - sich auf unsere Fähigkeit völlig zu verlassen, ihren Bankverkehrsvoraussetzungen in verschiedenen Erdkunden zu dienen. Finden Sie heraus wohnt über unsere Internationale Anwesenheit, und wie es auch verfolgt, vom Vorteil zu Ihrer Einrichtung sein. Trotz der Tatsache, dass zur großen Zahl unserer internationalen Einheitspflüge tief verbunden mit der Bestimmung von Dienstleistungen zu portugiesischen Emigrant-Gemeinschaften auswärts BES Gruppentätigkeiten Ass pflügen, änderte Experten seine globale Ausbreitung. Zur Liste der relevantesten internationalen Tätigkeiten hilft Zusammenstellung des breiten Spielraums der globalen BES Anwesenheit: Dienstleistungen zu Emigrant-Gemeinschaften (Kontoöffnung, Sparkonten, Überweisungen
 

Ich weiß nicht, wo du diese Meldung her hast. Wenn ich mich aber recht erinnere, wurde vor einigen Monaten bei "Great West Gold" die Fake-Meldung verbreitet, dass sie von einer portugiesischen Bank übernommen werden soll. Meiner Erinnerung nach war es genau dieselbe Bank. Gleiches wurde später bei einer anderen Firma berichtet, die mir nicht mehr einfällt.
Also alles Lug&Betrug!  

bei GW wurde die Meldung ja gleich Dementiert
hier glaube ich noch nicht
aber scheint wohl nichts dran zu sein
gibt nichts was dies Mail bestätigt

Immer auf der Hut sein,echt schlimm  

genau - deis habe ich auch gedacht.
vor einige monate wurde diese meldung auch gebracht (auch portugiesise bank, auch eine OTCBB aktie - weiss leider auch nicht mehr welche, vielleicht USXP oder VMCS)

vorsicht ist hier angebracht

izzy  

aber die Gesellschaft hat ja einen einfachen Halskrebstest entwickelt der nun vermarktet wird, das sollte auch schon "Schub" genug sein;-)Anscheinend wirkliche Früherkennung da er bereits Antikörper feststellt die ja sofort vom Körper bei den ersten Anzeichen von Ausbruch gebildet werden.
Gruß Hausi  

Berlin/Bremen  0,017    bG   32.338  +13,33%
Nasdaq OTC BB ($) 0,024       519.600  +9,09%
Da könnte noch was gehen, oder was sagt Ihr?
Gruß Hausi